Quarterly report · Q3

Period2023-04-01 → 2023-12-31
Filed2024-02-07
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 59
MetricValuePeriodScopeSource row
Revenue¥1.81T2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥620.0bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥2.90T2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥2.26T2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥728.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income−¥160.6bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income−¥27.0bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥71.4bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥10.9bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax−¥160.0bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax−¥56.2bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥231m2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥94.8bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax−¥32.0bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)−¥109.8bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥33.4bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥60.3bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥20.8bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income−¥164.9bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income−¥57.9bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income−¥46.9bn2022-04-01 → 2023-03-31Cons.Profit loss IFRS (5-year summary)
Net income¥41.7bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income−¥31.4bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥4.22Tat 2023-12-31Cons.Assets IFRS
Total assets¥4.17Tat 2023-03-31Cons.Assets IFRS
Total assets¥4.55Tat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥2.77Tat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥2.68Tat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.45Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥1.49Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.80Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥1.70Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.16Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.17Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.31Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥276.2bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥305.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥499.6bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥365.4bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥135.0bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥111.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥100.3bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥77.8bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥19.4bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥1.7bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥161.1bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥178.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥13.0bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-67.132023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥-20.442023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥4.272022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥36.892022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥-12.692022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥4.272022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥36.882022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
Equity ratio27.5%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio28.1%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio28.8%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 124
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-12-31¥111.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-10-01 → 2023-12-31¥35.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-12-31¥50.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-10-01 → 2023-12-31¥15.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-12-31¥61.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-10-01 → 2023-12-31¥20.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-12-31¥8.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-10-01 → 2023-12-31¥4.0bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥81.0bn
Reconciling Itemsreconcilingrevenue2023-10-01 → 2023-12-31−¥25.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥81.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-10-01 → 2023-12-31−¥25.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥9.5bn
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2023-12-31−¥1.6bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentrevenue2023-04-01 → 2023-12-31¥238.1bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentrevenue2023-10-01 → 2023-12-31¥78.3bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2023-04-01 → 2023-12-31¥225.3bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2023-10-01 → 2023-12-31¥75.4bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥12.8bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥2.9bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2023-04-01 → 2023-12-31¥9.4bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2023-10-01 → 2023-12-31¥2.9bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2023-04-01 → 2023-12-31¥600.8bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2023-10-01 → 2023-12-31¥207.8bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2023-04-01 → 2023-12-31¥596.7bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2023-10-01 → 2023-12-31¥206.4bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥4.2bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥1.4bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2023-04-01 → 2023-12-31−¥62.0bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2023-10-01 → 2023-12-31−¥17.6bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2023-04-01 → 2023-12-31¥369.4bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2023-10-01 → 2023-12-31¥126.3bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2023-04-01 → 2023-12-31¥367.0bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2023-10-01 → 2023-12-31¥125.8bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥2.4bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥521m
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2023-04-01 → 2023-12-31−¥1.4bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2023-10-01 → 2023-12-31¥6.2bn
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentrevenue2023-04-01 → 2023-12-31¥311.4bn
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentrevenue2023-10-01 → 2023-12-31¥107.5bn
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2023-04-01 → 2023-12-31¥311.1bn
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2023-10-01 → 2023-12-31¥107.4bn
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥331m
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥111m
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2023-04-01 → 2023-12-31¥36.8bn
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2023-10-01 → 2023-12-31¥19.0bn
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentrevenue2023-04-01 → 2023-12-31¥256.4bn
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentrevenue2023-10-01 → 2023-12-31¥89.5bn
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentrevenue external2023-04-01 → 2023-12-31¥256.4bn
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentrevenue external2023-10-01 → 2023-12-31¥89.5bn
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥2m
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥1m
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentsegment profit2023-04-01 → 2023-12-31−¥95.6bn
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentsegment profit2023-10-01 → 2023-12-31−¥30.1bn
—segment totalrevenue2023-04-01 → 2023-12-31¥1.78T
—segment totalrevenue2023-10-01 → 2023-12-31¥609.3bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥1.76T
—segment totalrevenue external2023-10-01 → 2023-12-31¥604.4bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥19.6bn
—segment totalrevenue intersegment2023-10-01 → 2023-12-31¥4.9bn
—segment totalsegment profit2023-04-01 → 2023-12-31−¥112.8bn
—segment totalsegment profit2023-10-01 → 2023-12-31−¥19.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥128.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-10-01 → 2022-12-31¥48.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥64.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-10-01 → 2022-12-31¥26.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥63.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-10-01 → 2022-12-31¥21.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31¥7.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-10-01 → 2022-12-31¥5.1bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥85.5bn
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥28.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥85.5bn
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥28.0bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥14.4bn
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥2.8bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentrevenue2022-04-01 → 2022-12-31¥270.7bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentrevenue2022-10-01 → 2022-12-31¥87.0bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2022-04-01 → 2022-12-31¥257.1bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2022-10-01 → 2022-12-31¥83.6bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥13.6bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥3.4bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2022-04-01 → 2022-12-31¥16.9bn
jpcrp040300-q3r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2022-10-01 → 2022-12-31¥3.4bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2022-04-01 → 2022-12-31¥680.1bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2022-10-01 → 2022-12-31¥209.8bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2022-04-01 → 2022-12-31¥675.5bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2022-10-01 → 2022-12-31¥208.2bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥4.6bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥1.6bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2022-04-01 → 2022-12-31−¥2.0bn
jpcrp040300-q3r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2022-10-01 → 2022-12-31−¥25.3bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2022-04-01 → 2022-12-31¥442.3bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2022-10-01 → 2022-12-31¥146.4bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2022-04-01 → 2022-12-31¥439.2bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2022-10-01 → 2022-12-31¥145.3bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥3.1bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥1.1bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2022-04-01 → 2022-12-31¥47.2bn
jpcrp040300-q3r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2022-10-01 → 2022-12-31¥10.9bn
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentrevenue2022-04-01 → 2022-12-31¥338.9bn
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentrevenue2022-10-01 → 2022-12-31¥116.5bn
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2022-04-01 → 2022-12-31¥338.6bn
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2022-10-01 → 2022-12-31¥116.4bn
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥350m
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥116m
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2022-04-01 → 2022-12-31¥43.7bn
jpcrp040300-q3r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2022-10-01 → 2022-12-31¥17.3bn
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentrevenue2022-04-01 → 2022-12-31¥482.5bn
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentrevenue2022-10-01 → 2022-12-31¥148.1bn
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentrevenue external2022-04-01 → 2022-12-31¥482.5bn
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentrevenue external2022-10-01 → 2022-12-31¥148.0bn
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥14m
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥7m
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentsegment profit2022-04-01 → 2022-12-31¥43.1bn
jpcrp040300-q3r_E00752-000Medical Productsreportable segmentsegment profit2022-10-01 → 2022-12-31¥17.9bn
—segment totalrevenue2022-04-01 → 2022-12-31¥2.21T
—segment totalrevenue2022-10-01 → 2022-12-31¥707.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥2.19T
—segment totalrevenue external2022-10-01 → 2022-12-31¥701.5bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥21.7bn
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥6.2bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥148.9bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥24.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,072
ItemContextValueUnit
Cash flows from used in investing activities IFRS (5-year summary)Prior1YearDuration-19411000000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YTDDuration12983000000JPY
Cash flows from used in financing activities IFRS (5-year summary)CurrentYTDDuration161104000000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YearDuration-178502000000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1QuarterInstant499594000000JPY
Cash and cash equivalents IFRS (5-year summary)CurrentQuarterInstant276152000000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1YearInstant305844000000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember1656449145
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember1656449145
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant1656449145
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant1656449145
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember20493100
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesReciprocalHoldingSharesWithFullVotingRightsTreasurySharesEtcMember1036300
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember1633348900
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember16333489
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember1570845
Number of shares issued shares voting rightsCurrentQuarterInstant1656449145
Number of voting rights issued shares voting rightsCurrentQuarterInstant16333489
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member20493100
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member20493100
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0123
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row2Member775500
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row2Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row2Member775500
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row2Member0.0004
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row3Member110800
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row3Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row3Member110800
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row3Member0.0000
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row4Member100000
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row4Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row4Member100000
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row4Member0.0000
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row5Member50000
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row5Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row5Member50000
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row5Member0.0000
Number of shares held in own name treasury shares etcCurrentQuarterInstant21529400
Number of shares held in others names treasury shares etcCurrentQuarterInstant-
Total number of shares held treasury shares etcCurrentQuarterInstant21529400
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0129
Cash and cash equivalents IFRSPrior1YearInstant305844000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant276152000000JPY
Trade and other receivables ca IFRSPrior1YearInstant603161000000JPY
Trade and other receivables ca IFRSCurrentQuarterInstant569080000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass